368 related articles for article (PubMed ID: 14654927)
41. The putative tumor suppressor gene FHIT at 3p14.2 is rarely affected by loss of heterozygosity in primary human brain tumors.
Frank S; Müller J; Plaschke J; Hahn M; Hampl J; Hampl M; Pistorius S; Schackert G; Schackert HK
Cancer Res; 1997 Jul; 57(13):2638-41. PubMed ID: 9205070
[TBL] [Abstract][Full Text] [Related]
42. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis.
Shimizu S; Yatabe Y; Koshikawa T; Haruki N; Hatooka S; Shinoda M; Suyama M; Ogawa M; Hamajima N; Ueda R; Takahashi T; Mitsudomi T
Clin Cancer Res; 2000 Oct; 6(10):3994-9. PubMed ID: 11051248
[TBL] [Abstract][Full Text] [Related]
43. PIK3CA mutations in glioblastoma multiforme.
Hartmann C; Bartels G; Gehlhaar C; Holtkamp N; von Deimling A
Acta Neuropathol; 2005 Jun; 109(6):639-42. PubMed ID: 15924253
[TBL] [Abstract][Full Text] [Related]
44. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
45. Influence of p53 mutations on prognosis of patients with glioblastoma.
Shiraishi S; Tada K; Nakamura H; Makino K; Kochi M; Saya H; Kuratsu J; Ushio Y
Cancer; 2002 Jul; 95(2):249-57. PubMed ID: 12124823
[TBL] [Abstract][Full Text] [Related]
46. Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas.
Bottarelli L; Azzoni C; Necchi F; Lagrasta C; Tamburini E; D'Adda T; Pizzi S; Sarli L; Rindi G; Bordi C
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4365-70. PubMed ID: 17671117
[TBL] [Abstract][Full Text] [Related]
47. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
48. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
49. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
50. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
Saxena A; Clark WC; Robertson JT; Ikejiri B; Oldfield EH; Ali IU
Cancer Res; 1992 Dec; 52(23):6716-21. PubMed ID: 1358438
[TBL] [Abstract][Full Text] [Related]
51. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
52. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma.
Ittmann MM
Prostate; 1996 May; 28(5):275-81. PubMed ID: 8610052
[TBL] [Abstract][Full Text] [Related]
53. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
54. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas.
Leone PE; Bello MJ; de Campos JM; Vaquero J; Sarasa JL; Pestaña A; Rey JA
Oncogene; 1999 Apr; 18(13):2231-9. PubMed ID: 10327069
[TBL] [Abstract][Full Text] [Related]
55. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
56. p53 mutation is a common genetic event in ovarian carcinoma.
Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
[TBL] [Abstract][Full Text] [Related]
57. [p53: an important or most overvalued tumor gene?].
Schlegel U
Laryngorhinootologie; 1994 Dec; 73(12):651-3. PubMed ID: 7840829
[TBL] [Abstract][Full Text] [Related]
58. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
[TBL] [Abstract][Full Text] [Related]
59. Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications.
Muhammad AK; Yoshimine T; Maruno M; Tokiyoshi K; Takemoto O; Ninomiya H; Hayakawa T
Clin Neuropathol; 1997; 16(4):220-6. PubMed ID: 9266149
[TBL] [Abstract][Full Text] [Related]
60. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing.
Badiali M; Iolascon A; Loda M; Scheithauer BW; Basso G; Trentini GP; Giangaspero F
Diagn Mol Pathol; 1993 Mar; 2(1):23-8. PubMed ID: 8287222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
